



Perosphere Presents Data on Investigational Anticoagulant Reversal Agent PER977 at 2014 American Heart Association (AHA) Annual Scientific Sessions in Chicago

Saturday, November 15, 2014

DANBURY, Conn.--(FOR IMMEDIATE RELEASE)--Perosphere Inc. will present data from studies involving the investigational anticoagulant reversal agent PER977 during the annual American Heart Association (AHA) Scientific Sessions in Chicago, November 15-19.

PER977 Poster Presentation

- Reversal of Anticoagulant-induced Bleeding in External and Internal Bleeding Models by PER977, a Small Molecule Anticoagulant Antidote
- Tuesday, November 18, 2014
- 3:00 PM to 4:30 PM Central Standard Time
- Presentation Number: 19361
- South Hall A2

About the Need for Anticoagulation Reversal

Anticoagulation is utilized for the treatment and prevention of thrombosis in upwards of seven million patients annually in the United States. Despite the volume of anticoagulants used, as many as half of the patients who are candidates for treatment do not receive appropriate therapy, often due to concerns by both physicians and patients regarding increased risk of hemorrhage and associated morbidity (intracranial hemorrhage, transfusion, hypovolemia, shock, compartment syndrome, cardiac arrest). An additional serious consideration among patients receiving anticoagulants is disruption of therapy in the event of emergency surgery or invasive procedures resulting in elevated risk of thrombosis in the interim.

In the United States for the 12 months ending June 2013, among patients treated with factor Xa- and IIa-inhibitor anticoagulants, it is estimated that approximately 918,000 patients experienced bleeding with approximately 345,000 emergency room and 227,000 hospital admissions. Current therapies for the management of bleeding secondary to anticoagulation are supportive. Therefore, a single reversal agent for low-molecular-weight heparin, unfractionated heparin and the new oral anticoagulants would provide an improved therapeutic option for these serious conditions while addressing an unmet medical need.

About PER977

PER977 is a small synthetic water-soluble new molecular entity that directly combines with heparins, fondaparinux and related anticoagulant drugs (i.e., direct Xa- and IIa- inhibitors) allowing rapid re-establishment of a normal blood coagulation state. This reversal effect is due to direct binding to the anticoagulant molecule with no binding to blood coagulation factors or to other proteins in the blood. PER977 is undergoing clinical development as a sterile, intravenous injection. Phase 2 studies are ongoing and nearing completion.



About Perosphere

Perosphere is a private specialty pharmaceutical company focused on developing rescue medications. For more information, please visit www.perosphere.com.

Contacts

Solomon S. Steiner, PhD
President & CEO
Perosphere Inc.
203-885-1116
s.steiner@perosphere.com

James C. Costin, MD
VP of Clinical & Medical Affairs, CMO
Perosphere Inc.
203-885-1369
j.costin@perosphere.com